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OBJECTIVES: Seeds are excellent sources of proteinase inhibitors, some of which may have satietogenic and
slimming actions. We evaluated the effect of a trypsin inhibitor from Tamarindus indica L. seeds on weight
gain, food consumption and cholecystokinin levels in Wistar rats.
METHODS: A trypsin inhibitor from Tamarindus was isolated using ammonium sulfate (30–60%) following
precipitation with acetone and was further isolated with Trypsin-Sepharose affinity chromatography. Analyses
were conducted to assess the in vivo digestibility, food intake, body weight evolution and cholecystokinin levels
in Wistar rats. Histological analyses of organs and biochemical analyses of sera were performed.
RESULTS: The trypsin inhibitor from Tamarindus reduced food consumption, thereby reducing weight gain. The
in vivo true digestibility was not significantly different between the control and Tamarindus trypsin inhibitor-
treated groups. The trypsin inhibitor from Tamarindus did not cause alterations in biochemical parameters or
liver, stomach, intestine or pancreas histology. Rats treated with the trypsin inhibitor showed significantly
elevated cholecystokinin levels compared with animals receiving casein or water.
CONCLUSION: The results indicate that the isolated trypsin inhibitor from Tamarindus reduces weight gain by
reducing food consumption, an effect that may be mediated by increased cholecystokinin. Thus, the potential
use of this trypsin inhibitor in obesity prevention and/or treatment should be evaluated.
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& INTRODUCTION
Obesity is considered an epidemic in the globalized
world. As the cost of treating obesity and its associated
diseases is high (1,2), investments in natural products that
may reduce dietary intake and weight gain are needed.
Thus, advances in scientific technical knowledge involving
quality, safety and efficacy, which are inherent to herbal
medicines, have placed the area of bioactive natural
products in a position of great interest in recent years. In
the treatment of obesity, factors such as the high cost and
the side effects of drugs, including those presented by
allopathic anorectics, have increased the demand for natural
products with slimming actions (3).
In this context, vegetable- and fruit-derived proteinase
inhibitors have been studied in animal models for their
effects on reducing energy consumption and/or food
intake. These studies confirm that endogenous cholecysto-
kinin (CCK) is important in the control of food intake.
Furthermore, protease inhibitors may have therapeutic
potential to reduce food intake by stimulating increases in
serum CCK (4–7).
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The tamarind fruit is often consumed in Brazil and almost
all of its parts are used. Although many therapeutic effects,
such as laxative, digestive and anti-diabetes effects are
locally attributed to this fruit (8,9), few studies have tested
the effect of this fruit or its extracts in vitro or in vivo.
Our group previously isolated a trypsin inhibitor from
tamarind seeds (TTI). This inhibitor is 20 kDa in size and
presented a non-competitive inhibition mechanism. TTI
inhibited the larval growth of Rhyzophertha dominica,
Anthonomus grandis and Ceratitis capitata by inhibiting
digestive enzymes and did not show inhibition either to
the serine proteases elastase and chymotrypsin or to the
cysteine proteases papain and bromelain (10). Thus, trypsin
inhibitors have been isolated and their heterologous actions
related to health benefits, such as anti-inflammatory,
gastroprotective and satiety control effects (7,12,13), have
been extensively investigated (11).
Nevertheless, it remains unclear whether these extracts
present effects in reducing food consumption and weight
gain and if these effects are CCK dependent. Thus, this
study investigated the effect of TTI in food consumption
and weight gain in rats. We also analyzed CCK levels in the
studied animals. Our results show a potential effect of TTI
in reducing food consumption and weight gain, possibly
mediated by increased CCK levels. This study shows that
isolated TTI may be a potential phytotherapeutic candidate
for preventing/treating obesity.
& MATERIALS AND METHODS
Materials
Chemicals and Reagents: CELM KitH (Sa˜o Paulo, Brazil);
Kit transferases from Labtest Diagnostic (Parana´, Brazil);
Kit Phoenix Pharmaceuticals Inc. (Burlingame, USA);
Soybean trypsin inhibitor, Kunitz type, from Sigma (St.
Louis, MO).
Tamarind fruit seeds
Tamarind fruits were obtained from markets in Natal, a
city from the Rio Grande do Norte state in northeastern
Brazil. Tamarind seeds were obtained after peeling and
removing the pulp using knives.
Isolation of the tamarind seed trypsin inhibitor
Isolation of the tamarind seed trypsin inhibitor followed
the methodology described by Arau´jo et al. (10), with
modifications. The modifications occurred in the step to
obtain TTI; once the fraction was saturated with 30–60%
ammonium sulfate from the crude extract, Tamarindus indica
L. seeds were precipitated with acetone 152 (v/v). The
fraction obtained after precipitation was isolated using
Trypsin-Sepharose 4B affinity chromatography, subjected to
dialysis for approximately 24 h against Tris-HCl buffer
(50 mM, pH 7.5), labeled TTI and then subjected to 12%
polyacrylamide gel electrophoresis in the presence of SDS.
All isolation steps were monitored and subjected to trypsin
inhibition assays using the specific substrate BApNA (N-
benzoyl-DL-arginine-p-nitroanilide) (14) and protein quan-
tification (15). Figure 1 shows the steps of the TTI isolation.
Animal study design
In this study, two animal experiments were conducted.
All experimental procedures were approved by the Animal
Ethics Committee of the Federal University of Rio Grande
do Norte state in Brazil (protocol No. 011/2010).
Experiment I
This first experiment was performed to assess the effect of
TTI on food consumption, weight gain and TTI digestibility
in rats. Male Wistar rats (n = 24) aged 3 months and
weighing 100 to 150 g were kept in cages in a vivarium at
23¡2 C˚ with a 12-hour light-dark cycle and humidity
between 45 and 55%. After 3 days of adaptation in metabolic
Figure 1 - Trypsin-Sepharose 4B affinity chromatography of the tamarind seed trypsin inhibitor (TTI). A) Elution profile of the retained
acetone-precipitated fraction (RPA). Adsorbed proteins were monitored at 280 nm (-). The inhibitory activity on trypsin (---) was
assayed using 100 mL of TTI. B) Denaturing electrophoresis on a 12% polyacrylamide gel after staining with Coomassie Brilliant Blue R-
250. M, Molecular mass markers; PA, precipitated with acetone; RPA, fraction obtained after precipitation with acetone isolated by
Trypsin-Sepharose affinity chromatography and TTI, tamarind trypsin inhibitor, isolated by Trypsin-Sepharose affinity chromatography
and subjected to dialysis. The arrows indicate 14 kDa for RPA and 20 kDa for TTI.
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cages, the rats were divided into 4 groups according to the
diets received for 11 days: 1) Standard diet, AIN-93G (S,
n = 6); 2) Standard diet, AIN-93G+1 mL of water (SW, n = 6);
3) Protein-free diet (PF, n = 6); 4) AIN-93G+25 mg/kg
tamarind trypsin inhibitor in 1 mL (25 mg/kg TTI, n = 6).
Water and TTI were given by oral gavage. Rats were
weighed daily using a calibrated scale. Food consumption
was registered daily, as described below. Feces were
individually collected on the 4th, 7th and 10th days, identified
and kept at -20 C˚ for digestibility analysis. The feces were
dried in a greenhouse with circulating air at 105 C˚ for 24 h,
cooled, weighed and crushed in a multiprocessor to
measure the total nitrogen levels (16). The apparent and
true digestibilities were then calculated (17).
On day 11, the rats were anesthetized with 2% xylazine
and 5% ketamine and then euthanized. Blood was collected
by cardiac puncture and stored in Falcon tubes. Serum was
separated by centrifugation at 3000 g for 10 min and used
for the measurement of glucose (GL), triacylglycerol (TG),
total cholesterol (COL) and high-density lipoprotein (HDL)
(Kit CELMH, Sa˜o Paulo, Brazil). The blood samples were
also subjected to enzymatic assays for alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) (Labtest
transferases diagnostic kit, Parana´, Brazil). Organs from
euthanized rats were assessed for histopathological altera-
tions as described below (18).
Experiment II
This experiment was performed to assess the effect of TTI
on short-term satiety and CCK production in rats. Male
Wistar rats (n = 36) aged 3 months and weighing 100 to
150 g were kept in cages in a vivarium at 23¡2 C˚ with a 12-
hour light-dark cycle and humidity between 45 and 55%. All
rats received standard diets (AIN-93G) ad libitum during this
experiment (19). After 3 days of adaptation in metabolic
cages, the rats were divided into 5 groups according to the
treatment received by oral gavage: 1) Standard diet, AIN-
93G+1 mL of water (SW, n = 6); 2) AIN-93G+25 mg/kg
Casein in 1 mL water (25 mg/kg C, n = 6); 3) AIN-
93G+25 mg/kg Soybean trypsin inhibitor in 1 mL water
(25 mg/kg IS, n = 6); 4) AIN-93G+25 mg/kg tamarind
trypsin inhibitor in 1 mL water (25 mg/kg TTI, n = 6); and
5) AIN-93G+50 mg/kg tamarind trypsin inhibitor in 1 mL
water (50 mg/kg TTI, n = 6).
Casein is a protein without inhibitory activity that was
used to discard the hypothesis that the effect of TTI could be
an unspecific protein effect. Soybean trypsin inhibitor was
used to compare the satietogenic effect of TTI once it was
well documented that soybean trypsin inhibitor promotes
satiety (6,20). Two different TTI concentrations were used to
verify whether the observed TTI effects were dose depen-
dent.
In experiment II, the rats were also weighed daily using a
calibrated scale. Food consumption was registered 1 h, 2 h
and 16 h after treatment, as described below. On day 11,
blood samples were taken 1 h after treatment for CCK
analysis, as described below. Next, rats were anesthetized
with 2% xylazine and 5% ketamine and then euthanized.
The blood was collected by cardiac puncture and stored in
Falcon tubes. Gamma glutamyl transferase was evaluated
by measuring the blood dosage (21). Total protein was
measured using the biuret method (22). Albumin was
measured using bromocresol green (BCG). The globulin
content was calculated as the difference between the total
protein and albumin and then the albumin/globulin ratio
was calculated. C-reactive protein was detected by agglu-
tination immune reaction using commercially available kits
(BioClin).
Assessment of food consumption and body weight
evolution
Food consumption was analyzed daily in all experiments
by calculating the difference between the diet provided
(before consumption) and the diet consumed using a
calibrated scale with 0.01 mg precision (Tecnal). In experi-
ment I, this calculation was performed as follows: food
consumption per day (g) = diet provided (g) - diet
consumed (g). The results for each day are expressed as
the mean food consumption (g) in each group. In experi-
ment II, the results are expressed as the percentage (%),
considered 100% of the average of the usual pattern of food
consumption of the rats before testing (3 days of adapta-
tion). Thus, after testing, the percentage decrease in
consumption (%) was obtained. In experiment I, weights
were also assessed daily using a calibrated scale with
0.01 mg precision (Tecnal). The results are expressed as the
mean weight gain per group.
Assessment of histopathological alterations
In experiment I, after the animals were euthanized, the
thoracic-abdominal cavity was opened. The intestines,
pancreas, stomach and liver were removed and fixed with
paraffin in blades using a standardized method (18).
Plasmatic CCK evaluation
In experiment II, plasmatic CCK was measured 1 h after
treatment by an immunoassay using commercially available
kits according to the manufacturer’s instructions (Phoenix
Pharmaceuticals Inc., Burlingame, USA).
Statistical analysis
Weight gain and food consumption were analyzed using
multifactor ANOVA to find possible differences between
groups. When significant differences were detected, Tukey’s
post-hoc test was used. CCK and the biochemical parameters
(GL, TG, total cholesterol, HDL, LDL, ALT, AST, GGT,
albumin and C-reactive protein) were analyzed and
compared between the different groups using Student’s t-
test and multifactorial ANOVA with Tukey’s post-hoc test.
Data were analyzed for normality and homoscedasticity
through the Kolmogorov-Smirnov test and Levene’s test,
respectively. All data were analyzed using the Statistica 7
software (Stat Soft, Tulsa, OK, USA).
& RESULTS AND DISCUSSION
TTI reduced weight gain and food consumption in
rats
As shown in Figure 2A, weight gain was significantly
lower in the animals treated with TTI in experiment I. By
treating one group with Standard diet (S) and another with
AIN-93G+1 mL of water given by gavage (SW), our data
reject the hypothesis that the gavage itself could reduce
weight gain. Interestingly, 25 mg/kg TTI treatment caused a
reduction in weight gain that was higher than the protein-
free diet.
Trypsin inhibitor increases CCK levels
Ribeiro JA et al.
CLINICS 2015;70(2):136-143
138
The food consumption data corroborates weight gain
data. Figure 2B shows that animals treated with 25 mg/kg
TTI had the lowest food consumption compared with the
other studied groups.
Mclaughlin et al. (23) analyzed the effect of the synthetic
trypsin inhibitor N,N-dimethyl-4-(4-guanidino-benzyloxy)-
phenyl ethyl methane-sulfate (DGPM) in obese and thin
Zucker rats. The administration of DGPM (25 to 200 mg/kg)
in rats after 6 h of fasting decreased food consumption in a
dose-dependent manner. A decrease in the mean size of the
meals was observed in both obese and thin rats.
Nevertheless, this effect was higher among the obese rats.
Furthermore, the administration of 100 mg/kg twice a day
for 7 days decreased food consumption and body weight in
obese rats but not in thin rats. This shows a specific
prominent action of DGPM in obese rats (23). In our study,
we did not evaluate obese rats.
As observed by Mclaughlin et al. (23) using DGPM, the
effects of TTI could possibly be potentiated in obese models.
Nevertheless, our data for normal Wistar rats are consistent,
thus indicating that further studies using obese models
should be performed to verify if the effects observed are
more prominent in an obese model.
A recent study evaluated the effect of concentrated potato
protease inhibitors (PPIC), potato protease inhibitor II and
casein at concentrations of 100 mg/kg administered for 10
days by oral gavage on food consumption and weight gain
in Wistar rats (180-200 g) (24). The authors found that casein
and PPIC significantly reduced food consumption. Similarly
to our results, the use of PPIC caused a reduction in weight
gain of 11%.
Nevertheless, our results show a more powerful effect of
TTI with a smaller dose (25 mg/kg) and the reduction in
weight gain was higher (approximately 70%). Furthermore,
we found a considerable effect on food consumption once
food consumption was reduced by 47%.
TTI treatment produced no effects on in vivo
digestibility
The satisfactory use of proteins for nutrition is dependent
on the protein composition, its amino acid bioavailability,
digestibility and the presence or absence of toxicity and anti-
nutritional factors (25,26). Thus, analyzing the digestibility
of 25 mg/kg TTI was important to assess whether the
reduction effects on weight gain and food consumption was
due to the existence of anti-nutritional factors that could
affect overall protein absorption.
Table 1 shows the digestibility results for the groups of
animals in experiment I. There were no significant differ-
ences between true digestibility and apparent digestibility
in the different groups studied. This excludes the hypothesis
that TTI could cause digestibility alterations that interfere
with the protein digestion/absorption process in treated
animals.
Not all trypsin inhibitors have the effect of reducing
weight gain without interfering with protein digestibility.
Some studies, using Wistar rats fed soybean trypsin
inhibitor, found a reduction in weight gain and food
consumption (27–29). However, soybean trypsin inhibitor
also reduced digestibility compared with casein, which was
not the case in our study.
TTI treatment did not alter the histopathology of
specific organs
Because oral administration of plant extracts may cause in
vivo damage to organs (27–30), in experiment I, we analyzed
the effect of 25 mg/kg TTI on the histopathology of the
Figure 2 - Wistar rats were subjected to oral gavage with the standard diet AIN-93G (S, n =6), standard diet AIN-93G+1 mL of water
(SW, n=6), protein-free diet (PF, n =6), or AIN-93G+25 mg/kg tamarind trypsin inhibitor in 1 mL water (25 mg/kg TTI, n=6) for 11 days.
A) The evolution of body weight, in grams (g). The results are expressed as the mean ¡ standard deviation of each group. Different
letters indicate p,0.05 using one-way ANOVA and Tukey’s post-hoc test. B) The average food intake in grams per day (g/day). The
results are expressed as the mean¡ standard deviation of each group. C) Assessment of the histopathological alterations in the SW and
TTI groups. A1 and A2: liver sections (406magnification); B1 and B2: stomach sections (106magnification); C1 and C2: pancreatic
sections (106magnifications); D1 and D2: bowel sections (106magnification).
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intestines, pancreas, stomach and liver. Figure 2C shows
that there were no alterations in the liver parenchyma of
treated animals: the stroma was preserved, the arterioles,
venules and capillaries were filled with normal red blood
cells, the membranes and nuclei were preserved and no
signs of cell death could be observed.
Animals treated with TTI also presented normal stomach
mucosa, intact gastric glands, no inflammatory infiltration
and intact submucosal, muscular and serous layers
(Figure 2C). The pancreas also showed no alterations,
exhibiting intact tissue, normal Langerhans islets and no size
alterations or cytoarchitectural distortion (Figure 2C). The
intestines also presented normal architecture and layers, with
no signs of inflammatory infiltration (Figure 2C).
These results are in accordance with those of other studies
that have found no histopathological variations in diverse
organs after treatment with trypsin inhibitors (20,31). Unlike
lectins (27), trypsin inhibitors do not seem to interact with
intestinal mucosal cells.
TTI produced no effects on the general biochemical
parameters of treated animals
The results of the biochemical analysis of the effect of
25 mg/kg TTI treatment in experiment I is shown in Table 2.
Glucose, total cholesterol, LDL, HDL and triglycerides were
not different between TTI-treated animals and controls. As
expected, glucose and triglycerides were significantly lower
in the animals that received the protein-free diet, possibly
due to an adaptation of metabolism because the feeding was
not balanced. The same effect was observed in experiment II
(Table 3), in which TTI at 25 mg/kg and 50 mg/kg doses
also did not cause significant alterations in glucose, total
cholesterol, HDL or triglycerides compared with the other
groups.
Interestingly, 25 mg/kg TTI treatment did not decrease
glucose levels after decreasing food consumption. This
absence of an effect on glucose levels was also observed in
experiment II, as shown in Table 3.
The liver enzymes ALT and AST were also similar
between the 25 mg/kg and 50 mg/kg TTI-treated and
control groups in both experiments I and II (Tables 2 and
3, respectively), which may indicate that the use of TTI did
not cause liver damage. Furthermore, gamma GT, analyzed
in experiment II, did not differ between the studied groups.
This is in agreement with the liver histopathological
analysis, which showed no significant alterations, suggest-
ing that TTI may be harmless to this tissue (Figure 2C).
To the best of our knowledge, this is the first study to
assess gamma GT in Wistar rats treated with trypsin
inhibitors. Nevertheless, Garthoff (20), in studies using pigs
given a partially purified trypsin inhibitor preparation,
found that GGT levels were not changed.
To corroborate the digestibility analyses, we also eval-
uated the effect of TTI on total protein, albumin and
globulin levels in experiment II. As shown in Table 3,
albumin levels did not differ between the groups studied,
showing that none of the treatments interfered with the
nutritional status of the animals. Globulin was significantly
lower in the 50 mg/kg TTI-treated and casein-treated
groups compared with the group fed a standard diet
(Table 3).
Globulin changes may indicate adaptation to stress.
Adapted animals tend to have normal values, whereas
stressed animals have increased levels (32,33). Thus, based
on the small decrease found in the 25 mg/kg and 50 mg/kg
TTI- and casein-treated groups, it is not likely that the
animals were stressed.
As globulin levels were different in the 50 mg/kg TTI-
and casein-treated groups compared with the control
groups, the albumin/globulin ratio was also significantly
different in these groups. Nevertheless, the total protein
levels were similar between the studied groups.
Table 1 - True digestibility and apparent digestibility in Wistar rats subjected to the standard diet AIN-93G (S, n= 6), AIN-
93G+1 mL of water (SW, n=6), AIN-93G+25 mg/kg tamarind trypsin inhibitor in 1 mL water (25 mg/kg TTI, n = 6) and
protein-free diet (PF, n = 6) for 11 days. The results are expressed as the mean ¡ standard deviation in each group.
Different lower case letters indicate p,0.05 between groups. Different upper case letters indicate p,0.05 between true
digestibility and apparent digestibility. One-way ANOVA followed by Tukey’s post-hoc test or Student’s t-test was used.
Treatment Urine nitrogen (%) Fecal nitrogen (%) True Digestibility (%) Apparent Digestibility (%)
S 1.12 1.75 90.70¡1.22aA 96.36¡0.91aB
SW 1.15 1.69 91.10¡1.02aC 96.68¡2.03aD
TTI 1.18 1.68 89.88¡0.94aE 92.58¡1.38aE
PF 0.18 0.39 - -
Table 2 - Biochemical parameters in Wistar rats subjected to the standard diet AIN-93G (S, n = 6), standard diet AIN-
93G+1 mL of water (SW, n=6), protein-free diet (PF, n = 6) and AIN-93G+25 mg/kg tamarind trypsin inhibitor in 1 mL
water (25 mg/kg TTI, n = 6) for 11 days. The results are expressed as the mean ¡ standard deviation of each group.
Different letters indicate p,0.05 between groups; one-way ANOVA followed by Tukey’s post-hoc test was used.
Groups Parameters S SW PF TTI 25 mg/kg
Glucose 151.2¡7.2a 162.3¡6.7a 93.0¡1.0b 158.1¡9.8a
Total cholesterol 51.4¡6.2a 59.7¡4.3a 54¡6.0b 41¡3.0a
LDL 19.8¡6.2a 32.7¡3.3b 18.0¡3.0a 24.3¡3.5a
HDL 24.2¡2.2a 23.8¡0.8a 20.0¡0.8b 24.6¡1.2a
Triglycerides 26.6¡1.4a 18.5¡6.7a 19.5¡5.8b 21.3¡4.7a
ALT 24.4¡4.6a 26.8¡5.1a 13.7¡0.3b 21.1¡1.0a
AST 82¡8.0a 91¡7.1ab 102¡7.0b 79¡6.2a
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Other studies using trypsin inhibitors have found no
alterations in glucose, cholesterol, triglycerides, total pro-
tein, globulin and albumin levels in pig (20), mice (34) and
rat (24,35) models.
To assess the possible induction of inflammation by
25 mg/kg and 50 mg/kg TTI, we also analyzed C-reactive
protein in the animals from experiment II. No alterations
were found and all groups presented similar C-reactive
protein concentrations (Table 3).
TTI increased short-term satiety and CCK levels
In experiment II, as shown in Figure 3A, food consump-
tion was significantly reduced after the 1st hour in mice
treated with TTI at 25 mg/kg and 50 mg/kg doses, with
values of 68.87¡1.80% and 56.80¡4.80%, respectively,
compared with that of the mice fed a standard diet (mean
reduction of 26.41¡2.86%) and of the animals that received
casein (mean reduction of 46.30¡3.27%). The same effect of
food consumption reduction was observed after the 2nd
hour of TTI treatment. Nevertheless, only TTI treatment at
50 mg/kg (54.50¡1.32%) resulted in a significant difference
between animals fed standard diet (18.86¡0.54%) and
animals given casein (25.74¡1.00%).
After 16 h of TTI treatment, a reduction in food
consumption was again observed. The 25 mg/kg TTI-
treated group displayed significantly reduced food con-
sumption (21.17¡0.89%) compared with the reduction
observed in the standard diet-fed (3.89¡1.29%), casein-
treated (13.67¡1.25%) and soybean trypsin inhibitor-treated
(9.89¡1.11%) groups.
Taken together, the results from our study show that TTI
at the studied doses may cause a reduction in food intake
during the 1st and 2nd hours after administration and that
this reduction may last until 16 h after treatment.
To evaluate whether the effect of TTI (25 mg/kg and
50 mg/kg) on reducing food consumption was CCK
associated, we evaluated plasmatic CCK levels in experi-
ment II. As shown in Figure 3B, CCK levels after 1 h of
treatment were significantly lower in the animals that
received a standard (5.92¡1.15 pmol/L) and casein diet
(10.14¡2.9 pmol/L) compared with the groups that
received trypsin inhibitors. Among these groups, those
treated with TTI at 25 mg/kg and 50 mg/kg presented the
highest CCK levels (17.41¡1.60 and 20¡1.22 pmol/L,
respectively). Interestingly, CCK levels in the animals that
received TTI at 50 mg/kg were significantly higher than
those in the animals treated with soybean trypsin inhibitor
(15.51¡1.82 pmol/L), an inhibitor with a well-known
satiety effect (36,37).
The effect of CCK on human satiety was first described by
Pi-Sunyer et al. (38) using exogenous CCK infusion.
Ballinger et al. (39) reported a 20% reduction in caloric
intake after a physiological infusion of CCK-8. In another
study, the effect of CCK-33 at physiological concentrations
on satiety was studied in slim and obese individuals. In this
study, CCK also promoted satiety and no differences in
nutritional status were observed (39). This is an interesting
finding because it indicates that natural molecules with the
potential to induce CCK secretion may be used to promote
satiety, thereby preventing or treating human obesity.
For the above reasons, trypsin inhibitors have been
studied. So far, few studies have been performed in
humans. Hill et al. (5) evaluated the effect of a potato
proteinase inhibitor (POT II) on food intake in 11 lean
individuals. A double-blind study was carried out and the
authors observed that the use of POT II 5 minutes before
lunch significantly reduced energy consumption by 17.5%.
In neonatal rats administered soybean trypsin inhibitor
(1 mg in 230 mL saline), an 87% increase in CCK plasmatic
concentrations was observed (36). Komarnytsky et al. (24)
also reported that the oral administration of a potato-
derived protease inhibitor concentrate (PPIC) was effective
in reducing food intake and weight gain in healthy rats by
increasing circulating CCK levels through a trypsin-depen-
dent mechanism.
Another study evaluated the effect of a potato extract that
included trypsin inhibitor proteins (Protein) in satiety and
CCK production by enteroendocrine cells. In this study,
soybean trypsin inhibitor was used as a positive control and
water was used as a negative control. The evaluation was
performed up to 6 h after administration. The results
showed that although soybean trypsin inhibitor and protein
reduced food intake, protein but not soybean trypsin
Table 3 - Biochemical parameters in Wistar rats fed the standard diet, AIN-93G+1 mL of water (SW, n=6), AIN-
93G+25 mg/kg casein in 1 mL water (25 mg/kg C, n=6), AIN-93G+25 mg/kg soybean trypsin inhibitor in 1 mL water
(25 mg/kg IS, n= 6); AIN-93G+25 mg/kg tamarind trypsin inhibitor in 1 mL water (25 mg/kg TTI, n =6), and AIN-
93G+50 mg/kg tamarind trypsin inhibitor in 1 mL water (50 mg/kg TTI, n = 6) for 11 days. The results are expressed as the
mean ¡ standard deviation of each group. Different letters indicate p,0.05 between groups; one-way ANOVA
followed by Tukey’s post-hoc test was used.
Groups Parameters SW C 25 mg/kg IS 25 mg/kg TTI 25 mg/kg TTI 50 mg/kg
Glucose 212¡35.9a 212¡64.8a 220¡38.2a 212¡58.0a 205¡57.5a
Total cholesterol 75.3¡9.8a 81.9¡12a 88.8¡10.5a 76.2¡2.1a 83.5¡8.4a
LDL 26.1¡8.1a 33.4¡1.4a 39¡12.6a 32.3¡9.3a 40.3¡6.7a
HDL 24.1¡3.8a 32.8¡6.3a 33.2¡6.9a 27.6¡3.3a 34.0¡6.5a
Triglycerides 82.2¡19.0a 102.5¡33.1a 75.0¡33.8a 59.0¡25.5a 64.7¡25.0a
ALT 78.4¡15.5a 60.4¡24.7a 67.5¡10.1a 57.5¡9.8a 59.7¡5.6a
AST 137.6¡16.9a 158.8¡26.6a 101.5¡35.2a 149.6¡36.4a 154¡49.4a
Gamma GT 5.5¡1.2a 7.0¡1.9a 10.6¡4.0a 9.7¡3.5a 8.9¡2.8a
Albumin 4.5¡0.3a 4.58¡0.8a 5.0¡0.5a 4.5¡0.1a 4.55¡0.1a
Globulin 4.2¡0.1a 3.3¡0.8b 4.0¡0.18ab 3.9¡0.5ab 3.1¡0.2b
ALB/GLO Ratio 1.1¡0.1a 1.4¡0.2b 1.3¡0.17ab 1.2¡0.2ab 1.47¡0.0b
Total protein 8.6¡0.7ab 7.9¡1.4ab 8.9¡0.4a 8.3¡0.7ab 7.6¡0.3b
C-reactive Protein NR NR NR NR NR
NR: Non-reactive.
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inhibitor dose-dependently induced CCK secretion in STC-1
cells (6).
To the best of our knowledge, this is the first in vivo study
using TTI, which comes from a very popular fruit in
northeastern Brazil. Our data, using TTI at 25 mg/kg and
50 mg/kg doses, possibly demonstrates that the effect of
TTI on increasing CCK is not dose dependent. Nevertheless,
further kinetic in vivo studies are needed to confirm this
hypothesis. Furthermore, this study showed that TTI has an
excellent effect on reducing weight gain and increasing
satiety. These effects are possibly mediated by stimulating
CCK production. To ensure that TTI is a promising
phytotherapeutic extract in the prevention and/or treatment
of obesity, more studies are needed to understand the
mechanisms by which TTI may induce CCK secretion. The
TTI signaling pathways and interactions with hormones and
adipokines also need to be studied.
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